Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists

References

• Burger JA, Ghia P, Rosenwald A, . The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367–3375.
   PubMed Web of Science ®Google Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43–52.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540–550.
   PubMed Web of Science ®Google Scholar
• Spoo AC, Lubbert M, Wierda WG, . CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007;109:786–791.
   PubMed Web of Science ®Google Scholar
• Konoplev S, Rassidakis GZ, Estey E, . Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007;109:1152–1156.
   PubMed Web of Science ®Google Scholar
• Kajiyama H, Shibata K, Terauchi M, . Involvement of SDF1-α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91–99.
   PubMed Web of Science ®Google Scholar
• Holm NT, Byrnes K, Li BDL, . Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 2007;141:53–59.
   PubMed Web of Science ®Google Scholar
• Ottaiano A, Franco R, Talamanca AA, . Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006;12:2795–2803.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kohara H, Noda M, . Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006;25:977–988.
   PubMed Web of Science ®Google Scholar
• Sipkins DA, Wei X, Wu JW, . In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005;435:969–973.
   PubMed Web of Science ®Google Scholar
• Blakrishnan K, Burger JA, Quiroga MP, . Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 2010;116:1083–1091.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, . Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441–4450.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927–2931.
   PubMed Web of Science ®Google Scholar
• Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to benchside. Clin Cancer Res 2008;14:7975–7980.
   PubMed Web of Science ®Google Scholar
• Azab AK, Runnels JM, Pitsillides C, . CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances sensitivity to therapy. Blood 2009;113:4341–4351.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Tamayo AT, Ford RJ, . Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009;113:4604–4613.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Samudio IJ, Munsell M, . Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006;5:3113–3121.
   PubMed Web of Science ®Google Scholar
• Burger M, Hartmann T, Krome M, . Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824–1830.
   PubMed Web of Science ®Google Scholar
• Fricker SP, Anastassov V, Cox J, . Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006;72:588–596.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, . Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, . Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• Bodart V, Anastassov V, Darkes MC, . Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol 2009;78:993–1000.
   PubMed Web of Science ®Google Scholar
• Nervi B, Ramirez P, Rettig MP, . Chemosensitization of actue myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009;113:6206–6214.
   PubMed Web of Science ®Google Scholar
• Kawaguchi A, Orba Y, Kimura T, . Inhibition of the SDF-1α-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-1 Tax transgenic mice. Blood 2009;114:2961–2968.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Shi YX, Samudio IJ, . Targeting the leukemia microenvironment by CCXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009;113:6215–6224.
   PubMed Web of Science ®Google Scholar
• Buchner M, Brantner P, Stickel N, . The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukemia – CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol 2010;151:167–178.
   PubMed Web of Science ®Google Scholar
• Kim K-M, Yoshimura T, Watanabe H, . Growth regulation of a human mature B cell line, B104, by anti-IgM and anti-IgD antibodies. J Immunol 1991;146:819–825.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, . Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9:5866–5873.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Zhao X, Triantafillou G, . A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 2008;14:569–578.
   PubMed Web of Science ®Google Scholar
• O'Hayre M, Salanga C, Kipps T, . Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One 2010;5:e11716.
   PubMed Web of Science ®Google Scholar
• Hubel K, Liles WC, Broxmeyer HE, . Leukocytosis and mobilization of CD34 + hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004;1:165–172.
   PubMedGoogle Scholar
• Andreeff M, Konoplev S, Wang R-Y, . Massive mobilization of AML cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: first evidence in patients and potential for abolishing bone marrow microenvironment-mediated resistance. Blood 2006;108(Suppl. 1): Abstract 568.
   Google Scholar
• Siders WM, Shields J, Garron C, . Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010;51:1293–1304.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, . Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005;46:1775–1784.
   PubMed Web of Science ®Google Scholar
• Martin C, Burdon PCE, Bridger G, . Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003;19:583–593.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Dell'Agnola C, Mancuso P, . CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106–3112.
   PubMed Web of Science ®Google Scholar